Anna Lena Ress

1.4k total citations · 1 hit paper
19 papers, 1.2k citations indexed

About

Anna Lena Ress is a scholar working on Molecular Biology, Cancer Research and Oncology. According to data from OpenAlex, Anna Lena Ress has authored 19 papers receiving a total of 1.2k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 9 papers in Cancer Research and 8 papers in Oncology. Recurrent topics in Anna Lena Ress's work include MicroRNA in disease regulation (7 papers), Circular RNAs in diseases (5 papers) and Signaling Pathways in Disease (4 papers). Anna Lena Ress is often cited by papers focused on MicroRNA in disease regulation (7 papers), Circular RNAs in diseases (5 papers) and Signaling Pathways in Disease (4 papers). Anna Lena Ress collaborates with scholars based in Austria, United States and Switzerland. Anna Lena Ress's co-authors include Martin Pichler, Armin Gerger, Gerald Höefler, Hellmut Samonigg, Michael Stotz, Joanna Szkandera, Peter Kornprat, Tatjana Stojaković, Wael Al Zoughbi and Carolin Lackner and has published in prestigious journals such as Journal of Clinical Oncology, PLoS ONE and International Journal of Molecular Sciences.

In The Last Decade

Anna Lena Ress

19 papers receiving 1.2k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer

2013 413 citations Michael Stotz, Armin Gerger et al. British Journal of Cancer profile →

Peers

Countries citing papers authored by Anna Lena Ress

Since Specialization

Citations

This map shows the geographic impact of Anna Lena Ress's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Anna Lena Ress with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Anna Lena Ress more than expected).

Fields of papers citing papers by Anna Lena Ress

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Anna Lena Ress. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Anna Lena Ress. The network helps show where Anna Lena Ress may publish in the future.

Co-authorship network of co-authors of Anna Lena Ress

This figure shows the co-authorship network connecting the top 25 collaborators of Anna Lena Ress. A scholar is included among the top collaborators of Anna Lena Ress based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Anna Lena Ress. Anna Lena Ress is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

#	Work	Indexed citations
1	SOX9 is a proliferation and stem cell factor in hepatocellular carcinoma and possess widespread prognostic significance in different cancer types 2017 ·PLoS ONE ·Georg Richtig, Ariane Aigelsreiter, Daniela Schwarzenbacher, Anna Lena Ress, (unknown), Verena Stiegelbauer, Gerald Höefler, Silvia Schauer, Tobias Kiesslich, Peter Kornprat, Thomas Winder, Florian Eisner, Armin Gerger, Herbert Stoeger, Rudolf Stauber, Carolin Lackner, Martin Pichler	46
2	Relevance of MicroRNA200 Family and MicroRNA205 for Epithelial to Mesenchymal Transition and Clinical Outcome in Biliary Tract Cancer Patients 2016 ·International Journal of Molecular Sciences ·(unknown), Christian Mayr, E. Klieser, (unknown), Doris Bach, Stefan Stättner, Florian Primavesi, (unknown), Stefanie Stanzer, Anna Lena Ress, (unknown), Andrej Wagner, Frieder Berr, Markus Ritter, Martin Pichler, Daniel Neureiter, Tobias Kiesslich	16
3	Comprehensive Analysis of miRNome Alterations in Response to Sorafenib Treatment in Colorectal Cancer Cells 2016 ·International Journal of Molecular Sciences ·(unknown), Anna Lena Ress, Stefanie Stanzer, (unknown), Michael Karbiener, Elke Stadelmeyer, Verena Stiegelbauer, Armin Gerger, Christian Mayr, Marcel Scheideler, Georg C. Hutterer, Thomas Bauernhofer, Tobias Kiesslich, Martin Pichler	30
4	microRNAs and Colorectal Cancer 2015 ·Advances in experimental medicine and biology ·Anna Lena Ress, Samantha Perakis, Martin Pichler	14
5	Low spinophilin expression enhances aggressive biological behavior of breast cancer 2015 ·Oncotarget ·Daniela Schwarzenbacher, Verena Stiegelbauer, Alexander Deutsch, Anna Lena Ress, Ariane Aigelsreiter, Silvia Schauer, Karin Wagner, Tanja Langsenlehner, (unknown), Armin Gerger, Hui Ling, Cristina Ivan, George A. Călin, Gerald Höefler, Beate Rinner, Martin Pichler	10
6	Multi-omics in prognosis of hepatocellular carcinoma. 2015 ·PubMed ·Anna Lena Ress, (unknown), Martin Pichler	2
7	MiR‐96‐5p influences cellular growth and is associated with poor survival in colorectal cancer patients 2014 ·Molecular Carcinogenesis ·Anna Lena Ress, Verena Stiegelbauer, Elke Winter, Daniela Schwarzenbacher, Tobias Kiesslich, Sigurd Lax, (unknown), Alexander Deutsch, Thomas Bauernhofer, Hui Ling, Hellmut Samonigg, Armin Gerger, Gerald Höefler, Martin Pichler	68
8	MiR-200a regulates epithelial to mesenchymal transition-related gene expression and determines prognosis in colorectal cancer patients 2014 ·British Journal of Cancer ·Martin Pichler, Anna Lena Ress, Elke Winter, Verena Stiegelbauer, Michael Karbiener, Daniela Schwarzenbacher, Marcel Scheideler, Cristina Ivan, Stephan Jahn, Tobias Kiesslich, Armin Gerger, Thomas Bauernhofer, George A. Călin, Gerald Höefler	99
9	Harvey ras (HRAS) mutations in head and neck cancer (HNC) and dependence on PI3K signaling and resistance to EGFR inhibition. 2014 ·Journal of Clinical Oncology ·Katharina Endhardt, Arun Khattri, Michaela K. Keck, Zhixiang Zuo, Damian Rieke, Anna Lena Ress, (unknown), (unknown), (unknown), Everett E. Vokes, Tanguy Y. Seiwert	1
10	Spinophilin expression determines cellular growth, cancer stemness and 5-flourouracil resistance in colorectal cancer 2014 ·Oncotarget ·Anna Lena Ress, Verena Stiegelbauer, Daniela Schwarzenbacher, Alexander Deutsch, Samantha Perakis, Hui Ling, Cristina Ivan, George A. Călin, Beate Rinner, Armin Gerger, Martin Pichler	18
11	miR-181a is associated with poor clinical outcome in patients with colorectal cancer treated with EGFR inhibitor 2013 ·Journal of Clinical Pathology ·Martin Pichler, Elke Winter, Anna Lena Ress, Thomas Bauernhofer, Armin Gerger, Tobias Kiesslich, Sigurd Lax, Hellmut Samonigg, Gerald Höefler	83
12	Validation of C-reactive protein levels as a prognostic indicator for survival in a large cohort of pancreatic cancer patients 2013 ·British Journal of Cancer ·Joanna Szkandera, Michael Stotz, Gudrun Absenger, Tatjana Stojaković, H. Samonigg, Peter Kornprat, Renate Schaberl-Moser, Wael Al Zoughbi, Carolin Lackner, Anna Lena Ress, F. Seggewies, Armin Gerger, Gerald Höefler, Martin Pichler	162
13	External Validation of the Derived Neutrophil to Lymphocyte Ratio as a Prognostic Marker on a Large Cohort of Pancreatic Cancer Patients 2013 ·PLoS ONE ·Joanna Szkandera, Michael Stotz, Florian Eisner, Gudrun Absenger, Tatjana Stojaković, Hellmut Samonigg, Peter Kornprat, Renate Schaberl-Moser, Wael Al Zoughbi, Anna Lena Ress, (unknown), Armin Gerger, Gerald Höefler, Martin Pichler	86
14	Comprehensive analysis of alterations in the miRNome in response to photodynamic treatment 2013 ·Journal of Photochemistry and Photobiology B Biology ·Doris Bach, (unknown), Michael Karbiener, Marcel Scheideler, Anna Lena Ress, Daniel Neureiter, Ralf Kemmerling, Otto Dietze, Markus Wiederstein, Frieder Berr, Kristjan Plaetzer, Tobias Kiesslich, Martin Pichler	23
15	Loss of the putative tumor suppressor protein spinophilin is associated with poor prognosis in head and neck cancer 2013 ·Human Pathology ·(unknown), Ariane Aigelsreiter, M. Wehrschuetz, Anna Lena Ress, Karin Koller, (unknown), Armin Gerger, Silvia Schauer, Thomas Bauernhofer, Martin Pichler	9
16	Increased neutrophil-lymphocyte ratio is a poor prognostic factor in patients with primary operable and inoperable pancreatic cancer breakdown → 2013 ·British Journal of Cancer ·Michael Stotz, Armin Gerger, Florian Eisner, Joanna Szkandera, Hans Loibner, Anna Lena Ress, Peter Kornprat, Wael Al Zoughbi, F. Seggewies, Carolin Lackner, Tatjana Stojaković, Hellmut Samonigg, Gerald Höefler, Martin Pichler	413
17	Preoperative neutrophil-to-lymphocyte ratio predicts clinical outcome in patients with stage II and III colon cancer. 2013 ·PubMed ·Gudrun Absenger, Joanna Szkandera, Michael Stotz, (unknown), Martin Pichler, Anna Lena Ress, Renate Schaberl-Moser, Hans Loibner, Hellmut Samonigg, Armin Gerger	47
18	Low expression of the putative tumour suppressor spinophilin is associated with higher proliferative activity and poor prognosis in patients with hepatocellular carcinoma 2013 ·British Journal of Cancer ·Ariane Aigelsreiter, Anna Lena Ress, Kira Bettermann, Silvia Schauer, Karin Koller, Florian Eisner, Tobias Kiesslich, Tatjana Stojaković, H. Samonigg, Peter Kornprat, Carolin Lackner, Johannes Haybaeck, Martin Pichler	20
19	MicroRNAs in renal cell carcinoma: implications for pathogenesis, diagnosis, prognosis and therapy. 2012 ·PubMed ·(unknown), Anna Lena Ress, Armin Gerger, Martin Pichler	34

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact